# CD4 new study: CAR-NK cells and HIV rebound in context

> A CD4-based CAR-NK paper on HIV rebound, placed in context with BioQ data on CD4: DepMap dependency, Open Targets diseases, drugs and Reactome pathways.

Data as of 2026-11-16 · Published 2026-11-16 · Updated 2026-11-16 · https://bioq.bio/blog/en/cd4-nk-cells-engineered-with-a-chimeric-antigen-receptor-delay-hiv-rebound

![BioQ results page for the query CD4 showing dependency, drug, disease association and pathway panels for the gene.](https://bioq.bio/blog/img/cd4-nk-cells-engineered-with-a-chimeric-antigen-receptor-delay-hiv-rebound/en/hero.webp)

A new Nature Communications paper uses a truncated CD4-based receptor to steer NK cells toward HIV-infected cells. As of 2026-11-16, BioQ shows CD4 with 0 dependent lines among 1178 DepMap cell lines, and HIV infectious disease as its top Open Targets association (score 0.734). Ten drugs are linked to CD4 in the drug data. The paper's results belong to the paper, not to BioQ.

## What we asked: what a new CD4 study touches

The paper (Nature Communications, DOI 10.1038/s41467-026-79036-0) engineers allogeneic NK cells with a CAR built from the CD4 domains D1 and D2. In this design CD4 is the binding part of the receptor. It recognises the conserved CD4 binding site on the HIV envelope. The authors then test the cells against infected primary CD4 T cells and in humanized mice, and they track barcoded virus and integration sites after ART interruption. We do not restate those results here.

The paper touches a different question from the one BioQ answers. It asks whether a CD4-derived receptor can help eliminate or reshape the reservoir. BioQ asks what public data say about the human gene CD4 itself:

- Is it a survival gene in cell lines?
- Which diseases and drugs are linked to it?
- Which pathways and protein partners surround it?

That context helps you judge how the CAR design relates to the biology of its binding domain.

## What BioQ returned for CD4

One query, "CD4", drew on 6 distinct resources and ran 7 engine queries in 4.04 engine seconds in total. The three tables below are the ones most relevant to the paper. The query also returned Reactome, STRING and TCGA/GTEx results, which are summarised in the next section.

![BioQ DepMap panel for CD4 listing CRISPR Chronos gene effect by lineage, with no dependent cell lines](https://bioq.bio/blog/img/cd4-nk-cells-engineered-with-a-chimeric-antigen-receptor-delay-hiv-rebound/en/dep.webp)
*DepMap Chronos view for CD4 in BioQ, by lineage.*

**CRISPR dependency (DepMap, release depmap_24q4).** Among 1178 cell lines, 0 are dependent. The mean Chronos gene effect is 0.03, and CD4 is not flagged as common essential. A more negative effect means the knockout reduced viability more. The lineages with the most negative means are listed here.

| Lineage | Cell lines | Dependent | % dependent | Mean gene effect |
|---|---|---|---|---|
| Testis | 5 | 0 | 0 | -0.041 |
| Pancreas | 47 | 0 | 0 | -0.012 |
| Biliary Tract | 35 | 0 | 0 | 0.002 |
| Lymphoid | 93 | 0 | 0 | 0.005 |
| Breast | 53 | 0 | 0 | 0.01 |
| Bowel | 63 | 0 | 0 | 0.018 |
| Myeloid | 42 | 0 | 0 | 0.021 |
| Ovary/Fallopian Tube | 59 | 0 | 0 | 0.024 |

**Drugs linked to CD4.** Open Targets, ChEMBL, the Drug Repurposing Hub and ClinicalTrials.gov together list 10 drugs. The table shows 8. The exact pChEMBL column is empty for all eight shown rows.

| Drug | Max clinical stage | Mechanism | Best exact pChEMBL | Type | Trials by name |
|---|---|---|---|---|---|
| Ibalizumab | APPROVAL | T-cell surface antigen CD4 inhibitor | — | — | 5 |
| Semzuvolimab | PHASE_3 | T-cell surface antigen CD4 inhibitor | — | — | 0 |
| Zanolimumab | PHASE_3 | T-cell surface antigen CD4 other | — | — | 1 |
| Clenoliximab | PHASE_2 | T-cell surface antigen CD4 inhibitor | — | — | 0 |
| Tregalizumab | PHASE_2 | T-cell surface antigen CD4 agonist | — | — | 2 |
| Vrc-01Ls | PHASE_1_2 | T-cell surface antigen CD4 binding agent | — | — | 0 |
| Priliximab | PHASE_1 | T-cell surface antigen CD4 negative modulator | — | — | 0 |
| Trx-1 | PHASE_1 | T-cell surface antigen CD4 inhibitor | — | — | 0 |

**Disease associations (Open Targets).** CD4 has associations with 3029 diseases. The six highest scores are below, on a scale of 0 to 1.

| Disease | Association score | Evidence items |
|---|---|---|
| HIV infectious disease | 0.734 | 11505 |
| immunodeficiency 79 | 0.572 | 17 |
| Okt4 epitope deficiency | 0.467 | 14 |
| HIV-1 infection | 0.4 | 3884 |
| viral infectious disease | 0.397 | 2434 |
| neurodegenerative disease | 0.371 | 91 |

**Pathways and partners.** Reactome lists 34 pathways for CD4. Among the most specific are "Binding and entry of HIV virion" (12 genes), "Nef Mediated CD4 Down-regulation" (10 genes) and "Early Phase of HIV Life Cycle" (22 genes). STRING v12 reports 4090 interaction partners. The top-scoring ones include CCR5, CXCR4, LCK and CD8A at 999, and IL16 at 998. TCGA/GTEx data cover 24 cancer types that have both tumour and normal samples. We do not use them for this paper.

## What it means and how to read it

**Dependency.** With 0 dependent lines out of 1178 and a mean gene effect of 0.03, CD4 does not behave like a gene that cancer cell lines need to survive. Even the lymphoid lineage (93 lines) shows 0 dependent and a mean of 0.005. This fits a lineage-restricted surface receptor and does not fit a housekeeping gene. It says nothing about how a CD4-derived receptor behaves inside an NK cell.

**Disease context.** The top Open Targets association is HIV infectious disease, with a score of 0.734 and 11505 evidence items. HIV-1 infection follows at 0.4 with 3884 items. Immunodeficiency 79 (0.572, 17 items) and Okt4 epitope deficiency (0.467, 14 items) are rare, low-evidence entries. The evidence counts differ by orders of magnitude, so read the score together with the number of items.

**Drugs.** Ibalizumab is listed at the APPROVAL stage with 5 trials found by name, and the mechanism is labelled as a CD4 inhibitor. The other seven shown agents range from PHASE_3 to PHASE_1, and the labels vary: inhibitor, other, agonist, binding agent, negative modulator. These are mechanism labels from the source databases. None of the shown rows has an exact potency value, so a potency comparison is not possible from this table. The listed agents are tools that engage the CD4 protein. The paper's CAR instead uses a CD4 fragment as a binder for the virus, so the two are different ways of using the same protein.

**Pathways and partners.** The Reactome entries about HIV entry and Nef-mediated CD4 down-regulation match the biology the paper builds on. The STRING partner CCR5 is notable because the paper's mouse model uses CCR5-tropic virus. A STRING score of 999 reflects combined evidence for association and does not describe the paper's experiments.

## How to reproduce it in BioQ

1. Open BioQ and type the gene symbol as the query.
2. Run the query exactly as below.

```text
CD4
```

[Open this query in BioQ](https://bioq.bio/login?next=%2Fapp%23q%3DCD4)

3. Open the DepMap panel and check the lineage table and the count of dependent lines.
4. Open the drug panel, then the Open Targets panel, and compare the stages, the mechanism labels and the evidence counts.
5. Open the Reactome and interaction panels and note which entries concern HIV entry and Nef.

Each answer names its source. Doing the same by hand means visiting six resources separately and matching gene identifiers between them. Here the engine time for all seven queries was 4.04 seconds.

## Limits: what the data do not show

- BioQ does not contain the paper's experiments. It cannot confirm or challenge its findings on viral rebound, barcoded lineages or integration sites.
- DepMap uses cancer cell lines. A result of 0 dependent lines says nothing about primary CD4 T cells, NK cells or the reservoir.
- Open Targets scores combine evidence types. A high score for HIV infectious disease reflects the amount of evidence, not the strength of any single link.
- Mechanism labels in the drug table come from source annotations and may group different agents under similar terms. The table has no exact potency values.
- STRING and Reactome describe known associations. They do not indicate what happens to a truncated CD4-derived receptor in an engineered NK cell.
- Nothing here is medical or treatment advice.

## Data and method
The numbers on this page were read from the BioQ engine on 2026-11-16 (7 queries, 4.0 s of engine time in total). The tables are generated by code from the engine's answers; the text only restates them.

`/depmap`, `/drugs`, `/interaction`, `/ot_association`, `/pathway`, `/tcga`

## Sources
- NK cells engineered with a chimeric antigen receptor delay HIV rebound and reshape HIV reservoir composition (2026) — [doi:10.1038/s41467-026-79036-0](https://doi.org/10.1038/s41467-026-79036-0)

Run the same query yourself: [CD4](https://bioq.bio/login?next=%2Fapp%23q%3DCD4)

*For research use only. This page summarises public data and is not medical advice.*

BioQ is an AI search engine and agent with one goal: making biology research 100X faster. Ask in the web app, over the REST API, or from Claude, ChatGPT or Cursor through MCP.

## Queries used

- [`CD4`](https://bioq.bio/login?next=%2Fapp%23q%3DCD4)

## Frequently asked questions

### Is CD4 a dependency in DepMap?

No. In DepMap release depmap_24q4, 0 of 1178 cell lines are dependent on CD4, the mean Chronos gene effect is 0.03, and CD4 is not flagged as common essential.

### Which disease is most associated with CD4 in Open Targets?

HIV infectious disease has the top score at 0.734, backed by 11505 evidence items. HIV-1 infection scores 0.4 with 3884 items. In total, 3029 diseases are associated with CD4.

### Which drugs target CD4 according to BioQ?

The drug data list 10 drugs for CD4, and 8 are shown. Ibalizumab is at the APPROVAL stage, and Semzuvolimab and Zanolimumab are at PHASE_3. No exact pChEMBL values are reported for the shown rows.

### Does BioQ show the results of the CD4-based CAR-NK paper?

No. The paper's results on HIV rebound and reservoir composition are the authors' own. BioQ shows public data on the CD4 gene, drawn from 6 distinct resources, to give context.

### Which proteins interact with CD4 in STRING?

STRING v12 lists 4090 partners. CCR5, CXCR4, LCK and CD8A score 999, and IL16 scores 998.

## Sources

- Paper: [NK cells engineered with a chimeric antigen receptor delay HIV rebound and reshape HIV reservoir composition](https://doi.org/10.1038/s41467-026-79036-0) (2026) DOI 10.1038/s41467-026-79036-0
- Dataset: [DepMap CRISPR Chronos gene effect (24Q4)](https://depmap.org/portal/)
- Dataset: [Open Targets Platform; ChEMBL; Drug Repurposing Hub](https://platform.opentargets.org/)
- Dataset: [TCGA pan-cancer expression (UCSC Xena Toil recompute)](https://xenabrowser.net/)
- Dataset: [Reactome pathway knowledgebase](https://reactome.org/)
- Dataset: [STRING v12 protein-protein interactions](https://string-db.org/)

> Results come from public databases as of the date shown and may change. BioQ gives research information, not medical advice.
